Use of accelerometry to investigate physical activity in dogs receiving chemotherapy

Article English OPEN
Helm, J. ; McBrearty, A. ; Fontaine, S. ; Morrison, R. ; Yam, P. (2016)

Objectives:\ud To perform a preliminary study to assess whether single-agent palliative or adjuvant chemotherapy has an impact on objectively measured physical activity in dogs.\ud \ud Methods:\ud Fifteen dogs with neoplasia (treatment group) wore ActiGraphâ„¢ accelerometers for 5-day periods before, during and after receiving single-agent adjuvant or palliative chemotherapy. Mean 5-day total physical activity and time spent in three different intensities of activity (sedentary, light-moderate and vigorous) before, during and after receiving chemotherapy were compared to a group of 15 healthy dogs (control group). Results were also compared within the treatment group across time.\ud \ud Results:\ud Prior to chemotherapy, treated dogs tended to be less active than control dogs. Treatment group dogs were slightly more active at restaging than they were prior to treatment but had similar activity levels to control dogs. Marked effects of chemotherapy on physical activity were not detected. Physical activity was slightly lower in treated dogs during chemotherapy when compared to control dogs but there was a slight increase in physical activity of treated dogs during chemotherapy when compared with pretreatment recordings. There was little change in the mean 5-day total physical activity between treated dogs during chemotherapy and at restaging but a mild decrease in time spent sedentary and increase in time spent in light-moderate activity at this comparison of time points.\ud \ud Clinical Significance:\ud Single-agent adjuvant or palliative chemotherapy had minimal impact on physical activity levels in dogs with neoplasia.
  • References (36)
    36 references, page 1 of 4

    1. Aaronson, N.K, Ahmedzai, S., Bergman, B. et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 85, 365-376

    2. ActiGraphTM (2013) https://help.theactigraph.com/entries/22041532 [accessed 4 May 2016]

    3. Backman, M., Wengstrom, Y., Johansson, B., et al. (2014) A randomized pilot study with daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer. Acta Oncologica 53, 510-520

    4. Bowles, D. B., Robson, N. M. C., Galloway, P. E., et al. (2010) Owners' perception of carboplatin in conjunction with other palliative treatments for cancer therapy Journal of Small Animal Practice 51, 104-112

    5. Carrison, M. and Hamrin, E. (1996) Measurement of quality of life in women with breast cancer. Development of a Life Satisfaction Questionnaire (LSQ-32) and a comparison with the EORTC QLQ-C30. Quality of Life Research 5, 265-274

    6. Corder, K., Ekelund, U., Steele, R.M., et al. (2008) Assessment of physical activity in youth. Journal of applied Physiology 105 977-987

    7. De Vries, S. I., Van Hirtum, H. W., Bakker, I. et al. (2009) Validity and reproducibility of motion sensors in youth: a systematic update. Medicine and Science in Sports and Exercise 41, 818-827

    8. Durante, R. and Ainsworth, B. E. (1996) The recall of physical activity: using a cognitive model of the question-answering process. Medicine and Science in Sports and Exercise 28, 1282-91

    9. Ehrhart, N.P., Ryan, S.D., & Fan, T.M. (2013) Tumors of the Skeletal System. In: Textbook of Small Animal Clinical Oncology. 5th edn. Eds S.J. Withrow, D.M. Vail and R.L. Page. Elsevier Saunders, Missouri. pp 482-483

    10. Fox, L. E., Rosenthal, R. C., King, R. R., et al. (2000) Use of cis-bis-neodecanoatotrans-R,R-1,2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma. American Journal of Veterinary Research 61, 791-795

  • Metrics
    No metrics available
Share - Bookmark